PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 65.7766

Change

-0.45 (-0.68)%

Market Cap

N/A

Volume

9.20K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.60 (-0.41%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.45 (-0.65%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-1.52 (-1.41%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-2.89 (-3.18%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.23 (-1.02%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.20 (-0.65%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.03 (+0.03%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.78 (-2.63%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.71%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.35 (-1.70%)

USD 6.67M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.13% 24% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.13% 24% F 31% F
Trailing 12 Months  
Capital Gain 0.33% 38% F 36% F
Dividend Return 0.05% 13% F N/A F
Total Return 0.38% 38% F 27% F
Trailing 5 Years  
Capital Gain 31.26% 43% F 58% F
Dividend Return 0.15% 11% F N/A F
Total Return 31.41% 43% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 4.73% 57% F 49% F
Dividend Return 4.75% 52% F 42% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 20.03% 48% F 54% F
Risk Adjusted Return 23.72% 52% F 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.